Picard Medical, Inc. 8-K

What Happened
Picard Medical, Inc. filed an 8-K reporting that CEO Patrick NJ Schnegelsberg notified the company on June 17, 2026 that he would step down as CEO and from the Board effective June 18, 2026, as part of a planned leadership transition. The Board appointed Richard Fang, Ph.D., the Company’s Chairman and former CEO, as Interim Chief Executive Officer effective June 18, 2026. The company issued a press release on June 24, 2026 announcing the transition.

Key Details

• Patrick NJ Schnegelsberg resigned as CEO and Board member effective June 18, 2026; his departure was not due to any disagreement with the company.
• Richard Fang, Ph.D. (Chairman and Board member since September 2021; PMI CEO from Sept 2021–July 2023) appointed Interim CEO and will continue as Chairman.
• Interim CEO compensation: $400,000 annual salary while serving in the interim role.
• A press release announcing the leadership change was furnished on June 24, 2026.

Why It Matters
A CEO change is a material corporate event that can affect strategy, operations, and investor confidence. The appointment of Richard Fang — an existing Chairman with prior CEO experience at Picard and a long history in medical devices — provides continuity while the Board searches for a permanent successor. Investors should watch for further disclosures about the search for a permanent CEO, any changes to strategic plans or guidance, and additional filings or proxy materials that may provide more detail.